Adempas
These highlights do not include all the information needed to use ADEMPAS safely and effectively. See full prescribing information for ADEMPAS.ADEMPAS (riociguat) tablets, for oral useInitial U.S. Approval: 2013
7b57509a-3d5d-41d4-8fed-1471e26372a3
HUMAN PRESCRIPTION DRUG LABEL
Jan 31, 2023
Bayer HealthCare Pharmaceuticals Inc.
DUNS: 005436809
Products 5
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
riociguat
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
riociguat
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (10)
riociguat
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
riociguat
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
riociguat
Product Details
FDA regulatory identification and product classification information